• OM-MSCs, Golgi Stress, and Stroke Recovery

  2026-09-10

  The reference study identifies a previously underdefined neuroprotective mechanism in which olfactory mucosa mesenchymal stem cells reduce Golgi apparatus stress after cerebral ischemia/reperfusion injury. Its data connect OM-MSC-derived PEDF with PI3K/Akt/mTOR signaling, reduced excessive autophagy, and improved control of GOLPH3-associated cellular injury, offering a mechanistic framework for future stroke research.

• KU-60019: ATM Kinase Inhibitor Workflow

  2026-09-10

  KU-60019 enables controlled ATM kinase signaling pathway inhibition for glioma radiosensitization, survival-pathway analysis, and migration or invasion studies. Its strong kinase selectivity and defined solvent profile support reproducible combination experiments when dosing, radiation timing, and vehicle controls are handled carefully.

• Peroxynitrite, Ca2+ Flux, and Cardiac Necroptosis

  2026-09-09

  Liu et al. identify a mechanistic cascade linking hyperhomocysteinemia to cardiac microvascular ischemia–reperfusion injury: Hcy and Cu2+ increase peroxynitrite, which drives ER stress, IP3R-dependent Ca2+ transfer, mitochondrial overload, and endothelial necroptosis. The study positions IP3R-mediated Ca2+ handling as an experimentally tractable intervention point while clarifying how microvascular injury may worsen acute cardiovascular outcomes.

• VX-765: Designing Causal Inflammasome Assays

  2026-09-09

  VX-765 and its active metabolite VRT-043198 provide a downstream strategy for testing caspase-1 dependence in cytokine release and pyroptosis. This article connects product chemistry with CARD8 inflammasome biology and practical assay design across macrophage and lymphocyte models.

• Capecitabine A8647: Reliable Assay Workflows

  2026-09-08

  This scenario-driven guide explains how Capecitabine (SKU A8647) can support more interpretable viability, proliferation, and cytotoxicity studies. It connects prodrug activation, tumor–stroma modeling, solution preparation, assay normalization, and vendor-quality checks to practical preclinical oncology workflows.

• Low-Dose Decitabine Restores Immune Tolerance in ITP

  2026-09-08

  The reference study shows that low-dose Decitabine, also known as 5-Aza-2'-deoxycytidine, can rebalance regulatory and effector T-cell populations in immune thrombocytopenia rather than acting only through increased platelet production. Its combination of patient samples, mechanistic cell assays, and active mouse models links Treg restoration to reduced STAT3 activation and provides a framework for studying immunomodulatory hypomethylating therapy.

• MCL-1 Dependence in Breast Cancer

  2026-09-07

  This 2021 study shows that established breast tumors depend on MCL-1 primarily because of its canonical anti-apoptotic control of BAX/BAK, rather than because of an independent non-apoptotic function. Genetic deletion and pharmacological inhibition produced anti-tumor effects that required BAX/BAK, providing a mechanistic rationale for selectively targeting MCL-1 in breast cancer research.

• RITA (NSC 652287): From p53 to Translation

  2026-09-07

  RITA (NSC 652287) offers a compelling model for linking MDM2-p53 pathway activation, DNA cross-linking, and time-resolved drug-response analysis. This thought-leadership guide shows how translational researchers can move beyond single-point viability measurements to distinguish growth arrest from cell death, interpret renal carcinoma data more rigorously, and design better-connected in vitro and tumor xenograft studies.

• DHEA: From Steroid Reagent to Translational Probe

  2026-09-05

  Dehydroepiandrosterone (DHEA) is more than an endogenous steroid hormone: it is a versatile translational probe linking steroidogenesis, cellular stress, apoptosis inhibition, neuroprotection, and ovarian biology. This article interprets recent PCOS research, defines practical experimental controls, and shows how APExBIO DHEA (SKU B1375) can support mechanistically disciplined workflows.

• Calpain, BDNF/TrkB, and Offspring Cognition

  2026-09-04

  The reference study identifies excessive calpain activation as a mechanistic link between maternal non-obstetric surgery during pregnancy and later cognitive impairment in rat offspring. Its rescue experiments connect calpain activity to disrupted hippocampal BDNF/TrkB signaling, synaptic structure, and behavior, providing a framework for studying protease-dependent neurodevelopmental injury.

• α-KG, LKB1–AMPK, and HPDLSC Senescence

  2026-09-04

  This 2026 Cellular Signalling study identifies an α-ketoglutarate/LKB1–AMPK axis that links mitochondrial recovery with reduced inflammation-induced senescence in human periodontal ligament stem cells. Its combined cell and animal evidence suggests that restoring mitochondrial homeostasis may improve osteogenic competence and periodontal regeneration, while also defining important boundaries for translation to other experimental systems.

• ABT-199 Workflow for Mitochondrial Apoptosis

  2026-09-03

  ABT-199 (Venetoclax) provides a selective way to test BCL-2 dependence in hematologic cancer models while limiting BCL-XL-associated confounding. This practical workflow combines dose-response analysis, orthogonal apoptosis readouts, and transcription-aware controls inspired by recent Pol II degradation research.

• CCT007093: A Practical PPM1D Inhibitor Workflow

  2026-09-03

  CCT007093 is a DMSO-soluble PPM1D inhibitor for linking phosphatase activity to P38 MAPK signaling, pyroptosis, and cell viability. This workflow separates early pathway activation from later cytotoxicity and adapts the compound for kidney-injury and breast-cancer research.

• Cepharanthine Workflows for Endometriosis Research

  2026-09-02

  Build a translational Cepharanthine workflow that progresses from stromal-cell viability and apoptosis research to patient-derived endometrial organoids and murine lesions. The approach combines formulation control, mechanism-resolved readouts, and troubleshooting designed to separate disease-relevant activity from nonspecific toxicity.

• LY-411575: Notch-to-Tumor Immune Assays

  2026-09-02

  LY-411575 is a highly potent gamma-secretase inhibitor for dissecting amyloid beta production and Notch biology. This article connects its biochemical activity to tumor-immune assay design, using recent TNBC findings to explain why timing, compartment, and immune readouts matter.

7071 records 1/472 page Next 12345 下5页 Last page